apexigen is a clinical-stage biopharmaceutical company discovering and developing innovative immuno-oncology therapeutics generated by apximab™, the company’s proprietary antibody drug discovery platform. its lead immuno-oncology drug candidate, apx005m, is a potent immune-activating antibody against cd40 currently in phase 2 clinical development.
Company profile
Ticker
APGN, APGNW
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Brookline Capital Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Apexigen America, Inc. ...
IRS number
851260244
APGN stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
5 Sep 23
S-8 POS
Registration of securities for employees (post-effective amendment)
23 Aug 23
8-K
Completion of Acquisition or Disposition of Assets
23 Aug 23
25-NSE
Exchange delisting
23 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
22 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Aug 23
DEFA14A
Additional proxy soliciting materials
16 Aug 23
8-K
Other Events
15 Aug 23
425
Business combination disclosure
11 Aug 23
425
Business combination disclosure
11 Aug 23
Financial summary
Quarter (USD) | Jun 23 | Mar 23 | Dec 22 | Sep 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 9.37 mm | 9.37 mm | 9.37 mm | 9.37 mm | 9.37 mm | 9.37 mm |
Cash burn (monthly) | 1.12 mm | 189.58 k | 2.05 mm | 2.32 mm | 1.00 mm | 2.19 mm |
Cash used (since last report) | 10.87 mm | 1.84 mm | 19.91 mm | 22.49 mm | 9.70 mm | 21.27 mm |
Cash remaining | -1.50 mm | 7.53 mm | -10.54 mm | -13.12 mm | -332.61 k | -11.90 mm |
Runway (months of cash) | -1.3 | 39.7 | -5.1 | -5.7 | -0.3 | -5.4 |
Institutional ownership, Q2 2023
28.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 36 |
Opened positions | 17 |
Closed positions | 2 |
Increased positions | 4 |
Reduced positions | 4 |
13F shares | Current |
---|---|
Total value | 1.35 bn |
Total shares | 7.00 mm |
Total puts | 0.00 |
Total calls | 16.45 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Decheng Capital China Life Sciences USD Fund II | 1.89 mm | $0.00 |
Decheng Capital Management III | 1.89 mm | $814.28 mm |
3E Bioventures Capital | 1.14 mm | $0.00 |
Fan Yu | 401.76 k | $172.68 mm |
Vanguard | 256.94 k | $110.43 mm |
BLK Blackrock | 213.83 k | $91.91 mm |
Geode Capital Management | 178.76 k | $76.83 mm |
Kepos Capital | 150.00 k | $5.00 k |
Walleye Capital | 106.21 k | $3.61 mm |
Yakira Capital Management | 85.00 k | $2.89 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
23 Aug 23 | Xiaodong Yang | Common Stock | Sale back to company | Dispose D | No | No | 0 | 863,729 | 0.00 | 0 |
23 Aug 23 | Xiaodong Yang | Common Stock | Payment of exercise | Dispose F | No | No | 0.3851 | 69,161 | 26.63 k | 863,729 |
23 Aug 23 | Xiaodong Yang | Common Stock | Grant | Acquire A | No | No | 0 | 400,000 | 0.00 | 932,890 |
23 Aug 23 | Xiaodong Yang | Warrant Common Stock | Sale back to company | Dispose D | No | No | 11.5 | 10,000 | 115.00 k | 0 |
23 Aug 23 | Xiaodong Yang | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 2.46 | 305,000 | 750.30 k | 0 |
23 Aug 23 | Xiaodong Yang | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.59 | 38,417 | 176.33 k | 0 |
23 Aug 23 | Xiaodong Yang | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 4.59 | 79,906 | 366.77 k | 0 |
23 Aug 23 | Xiaodong Yang | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 7.03 | 12,296 | 86.44 k | 0 |
23 Aug 23 | Xiaodong Yang | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.54 | 99,373 | 649.90 k | 0 |
23 Aug 23 | Xiaodong Yang | Employee Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.62 | 295,978 | 1.07 mm | 0 |